vs

Side-by-side financial comparison of Cellebrite DI Ltd. (CLBT) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

Cellebrite DI Ltd. is the larger business by last-quarter revenue ($292.2M vs $197.9M, roughly 1.5× REPLIGEN CORP). REPLIGEN CORP runs the higher net margin — 6.7% vs -103.5%, a 110.2% gap on every dollar of revenue. Cellebrite DI Ltd. produced more free cash flow last quarter ($60.8M vs $17.6M). Over the past eight quarters, Cellebrite DI Ltd.'s revenue compounded faster (72.8% CAGR vs 14.4%).

Cellebrite DI Ltd. is a digital forensics company headquartered in Petah Tikva, Israel that provides tools for law enforcement agencies as well as enterprise companies and service providers to collect, review, analyze and manage digital data. Their flagship product series is the Cellebrite UFED.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

CLBT vs RGEN — Head-to-Head

Bigger by revenue
CLBT
CLBT
1.5× larger
CLBT
$292.2M
$197.9M
RGEN
Higher net margin
RGEN
RGEN
110.2% more per $
RGEN
6.7%
-103.5%
CLBT
More free cash flow
CLBT
CLBT
$43.3M more FCF
CLBT
$60.8M
$17.6M
RGEN
Faster 2-yr revenue CAGR
CLBT
CLBT
Annualised
CLBT
72.8%
14.4%
RGEN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
CLBT
CLBT
RGEN
RGEN
Revenue
$292.2M
$197.9M
Net Profit
$-302.3M
$13.3M
Gross Margin
84.6%
52.5%
Operating Margin
14.1%
9.0%
Net Margin
-103.5%
6.7%
Revenue YoY
13.6%
Net Profit YoY
143.9%
EPS (diluted)
$-1.50
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBT
CLBT
RGEN
RGEN
Q4 25
$197.9M
Q3 25
$292.2M
$188.8M
Q2 25
$220.8M
$182.4M
Q1 25
$89.6M
$169.2M
Q4 24
$174.1M
Q3 24
$232.1M
$154.9M
Q2 24
$185.3M
$154.1M
Q1 24
$71.2M
$151.3M
Net Profit
CLBT
CLBT
RGEN
RGEN
Q4 25
$13.3M
Q3 25
$-302.3M
$14.9M
Q2 25
$36.9M
$14.9M
Q1 25
$-71.4M
$5.8M
Q4 24
$-30.3M
Q3 24
$-654.0K
Q2 24
$-95.2M
$3.3M
Q1 24
$-40.6M
$2.1M
Gross Margin
CLBT
CLBT
RGEN
RGEN
Q4 25
52.5%
Q3 25
84.6%
53.2%
Q2 25
84.1%
50.0%
Q1 25
85.2%
53.6%
Q4 24
26.1%
Q3 24
83.5%
50.0%
Q2 24
84.1%
49.8%
Q1 24
82.6%
49.5%
Operating Margin
CLBT
CLBT
RGEN
RGEN
Q4 25
9.0%
Q3 25
14.1%
8.9%
Q2 25
12.1%
7.6%
Q1 25
10.3%
3.9%
Q4 24
-17.7%
Q3 24
7.9%
-5.1%
Q2 24
11.7%
1.0%
Q1 24
0.2%
1.3%
Net Margin
CLBT
CLBT
RGEN
RGEN
Q4 25
6.7%
Q3 25
-103.5%
7.9%
Q2 25
16.7%
8.2%
Q1 25
-79.7%
3.4%
Q4 24
-17.4%
Q3 24
-0.4%
Q2 24
-51.4%
2.2%
Q1 24
-57.0%
1.4%
EPS (diluted)
CLBT
CLBT
RGEN
RGEN
Q4 25
$0.24
Q3 25
$-1.50
$0.26
Q2 25
$0.15
$0.26
Q1 25
$-0.36
$0.10
Q4 24
$-0.55
Q3 24
$-0.35
$-0.01
Q2 24
$-0.48
$0.06
Q1 24
$-0.21
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBT
CLBT
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$191.7M
$767.6M
Total DebtLower is stronger
$542.2M
Stockholders' EquityBook value
$336.0M
$2.1B
Total Assets
$690.6M
$2.9B
Debt / EquityLower = less leverage
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBT
CLBT
RGEN
RGEN
Q4 25
$767.6M
Q3 25
$191.7M
$748.7M
Q2 25
$326.1M
$708.9M
Q1 25
$191.7M
$697.2M
Q4 24
$757.4M
Q3 24
$189.5M
$784.0M
Q2 24
$178.6M
$809.1M
Q1 24
$189.5M
$780.6M
Total Debt
CLBT
CLBT
RGEN
RGEN
Q4 25
$542.2M
Q3 25
$537.9M
Q2 25
Q1 25
Q4 24
$525.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CLBT
CLBT
RGEN
RGEN
Q4 25
$2.1B
Q3 25
$336.0M
$2.1B
Q2 25
$408.4M
$2.1B
Q1 25
$336.0M
$2.0B
Q4 24
$2.0B
Q3 24
$34.2M
$2.0B
Q2 24
$-40.2M
$2.0B
Q1 24
$34.2M
$2.0B
Total Assets
CLBT
CLBT
RGEN
RGEN
Q4 25
$2.9B
Q3 25
$690.6M
$2.9B
Q2 25
$787.4M
$2.9B
Q1 25
$690.6M
$2.9B
Q4 24
$2.8B
Q3 24
$532.9M
$2.8B
Q2 24
$556.6M
$2.9B
Q1 24
$532.9M
$2.8B
Debt / Equity
CLBT
CLBT
RGEN
RGEN
Q4 25
0.26×
Q3 25
0.26×
Q2 25
Q1 25
Q4 24
0.27×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBT
CLBT
RGEN
RGEN
Operating Cash FlowLast quarter
$66.2M
$25.7M
Free Cash FlowOCF − Capex
$60.8M
$17.6M
FCF MarginFCF / Revenue
20.8%
8.9%
Capex IntensityCapex / Revenue
1.8%
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$172.1M
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBT
CLBT
RGEN
RGEN
Q4 25
$25.7M
Q3 25
$66.2M
$48.1M
Q2 25
$53.5M
$28.6M
Q1 25
$10.0M
$15.0M
Q4 24
$39.2M
Q3 24
$58.2M
$49.3M
Q2 24
$24.6M
$42.2M
Q1 24
$12.5M
$44.7M
Free Cash Flow
CLBT
CLBT
RGEN
RGEN
Q4 25
$17.6M
Q3 25
$60.8M
$43.4M
Q2 25
$47.5M
$21.5M
Q1 25
$8.5M
$11.4M
Q4 24
$33.6M
Q3 24
$55.3M
$42.3M
Q2 24
$21.0M
$37.4M
Q1 24
$11.4M
$36.4M
FCF Margin
CLBT
CLBT
RGEN
RGEN
Q4 25
8.9%
Q3 25
20.8%
23.0%
Q2 25
21.5%
11.8%
Q1 25
9.5%
6.8%
Q4 24
19.3%
Q3 24
23.8%
27.3%
Q2 24
11.3%
24.3%
Q1 24
16.0%
24.0%
Capex Intensity
CLBT
CLBT
RGEN
RGEN
Q4 25
4.1%
Q3 25
1.8%
2.5%
Q2 25
2.7%
3.9%
Q1 25
1.7%
2.1%
Q4 24
3.2%
Q3 24
1.3%
4.5%
Q2 24
1.9%
3.1%
Q1 24
1.5%
5.5%
Cash Conversion
CLBT
CLBT
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.45×
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLBT
CLBT

Subscription services$197.2M67%
Term-license$60.8M21%
Professional services$23.2M8%
Other non-recurring$11.0M4%

RGEN
RGEN

Segment breakdown not available.

Related Comparisons